SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Alam Kamran	Date of Event 3. Issuer Name and Ticker or Trading Symbol equiring Statement AQUINOX PHARMACEUTICALS, INC [AQXP] 3/06/2014 3. Issuer Name and Ticker or Trading Symbol						
(Last)(First)(Middle)C/O AQUINOX PHARMACEUTICALS, INC.450 - 887 GREAT NORTHERN WAY(Street)VANCOUVER A1V5T 4T5(City)(State)(Zip)			4. Relationship of Reporting Perso (Check all applicable) Director X Officer (give title below) CFO, Vice President	10% Owne Other (spe below)	er (Mor cify 6. In	hth/Day/Year) dividual or Joint icable Line) Form filed b	ate of Original Filed /Group Filing (Check y One Reporting Person y More than One erson
Table I - Non-Derivative Securities Beneficially Owned							
1. Title of Security (Instr. 4)			. Amount of Securities teneficially Owned (Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)	
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Underlying Derivative Securit		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	(1)	08/21/2021	Common Stock ⁽²⁾	20,833	5.76	D	
Stock Option (Right to Buy)	(1)	05/29/2022	Common Stock ⁽²⁾	10,416	5.76	D	
Stock Option (Right to Buy)	(1)	10/30/2023	Common Stock ⁽²⁾	23,598	12.67	D	

Explanation of Responses:

1. The option securities subject to this option shall vest and become exercisable at a rate of twenty-five percent of the option securities underlying the options on the one-year anniversary of the vesting commencement date and 1/48th of the option securities underlying the options each monthly anniversary of the vesting commencement date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total option securities underlying the options shall be fully vested on the four-year anniversary of the vesting commencement date. However, if Mr. Alam terminates his employment for good reason within 12 months following a change of control, 100% of the then unvested shares immediately become fully vested.

2. Each option granted under the issuer's Joint Canadian Stock Option Plan is exercisable for one "option security." Prior to the closing of the issuer's initial public offering, an option security is comprised of one common exchangeable share and one special voting share of Aquinox Pharmaceuticals Inc., a corporation under the Canadian Business Corporations Act. Following the closing of the issuer's initial public offering, an option security will be comprised of one share of the issuer's common stock.

Remarks:

/s/ Kamran Alam

** Signature of Reporting Person

Date

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

03/06/2014